Rexahn Pharmaceuticals Inc (NYSE American:RNN)

1.57
Delayed Data
As of Jun 22
 +0.03 / +1.95%
Today’s Change
1.42
Today|||52-Week Range
3.19
-22.28%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$67.9M

Company Description

Rexahn Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the research and development of oncology therapeutics. Its drug candidates include the following: RX-31171 for pancreatic, bladder, colon, and lung cancer; RX-5902 or Supinoxin for metastatic triple negative breast cancer; and RX-0201 or Archexin for renal cell carcinoma, glioblastoma, ovarian, stomach, and pancreatic cancer. It also develops nano-based drug delivery systems. The company was founded by Chang Ho Ahn on March 19, 2001 and is headquartered in Rockville, MD.

Contact Information

Rexahn Pharmaceuticals, Inc.
15245 Shady Grove Road
Rockville Maryland 20850
P:(240) 268-5300
Investor Relations:

Employees

Shareholders

Mutual fund holders4.43%
Other institutional1.02%
Individual stakeholders0.08%

Top Executives

Peter David SuzdakChief Executive Officer & Director
Douglas J. SwirskyPresident, Chief Financial Officer & Secretary
Ely BenaimChief Medical Officer
Lisa M. NolanChief Business Officer